The European Registry of Older Subjects With Atrial Fibrillation (EUROSAF)

Last updated: September 6, 2023
Sponsor: Alberto Pilotto
Overall Status: Active - Recruiting

Phase

N/A

Condition

Arrhythmia

Chest Pain

Cardiac Disease

Treatment

N/A

Clinical Study ID

NCT02973984
28UCS2015
162REG2016
  • Ages > 65
  • All Genders

Study Summary

Preliminary data suggest that:

  1. a different risk of mortality, as assessed by the Multidimensional Prognostic Indices (MPI), may influence the anticoagulant prescription in older subjects with Atrial Fibrillation (AF);

  2. the presence of multidimensional impairment, disability and multi-morbidities are usually not included in the decision algorithm of the more appropriate treatments in older patients with AF;

  3. considering the prognostic information, as calculated by the MPI, can be useful to physicians in identifying older patients with AF that can benefit from anticoagulant treatment in term of increased survival.

Eligibility Criteria

Inclusion

Inclusion Criteria: This is an observational study in which all consecutive patients admitted to the GeriatricsUnits involved in the project will be screened for inclusion. The inclusion criteria are:

  1. patients of both genders, aged 65 years and older
  2. admitted to hospital for acute diseases or a relapse of chronic diseases
  3. with a documented diagnosis of non valvular AF
  4. who are willing to participate in the survey and give their informed consent

Exclusion

Exclusion Criteria:

  1. age less than 65 years
  2. patients who have not provided informed consent

Study Design

Total Participants: 3000
Study Start date:
November 18, 2016
Estimated Completion Date:
December 31, 2024

Study Description

The main objective of this observational study is to evaluate in a "real world" population of older hospitalized patients with AF, the clinical benefit/risk ratio of the anticoagulant treatments in terms of:

  1. mortality (all-cause and vascular mortality);

  2. thromboembolic events, i.e. stroke, systemic embolism;

  3. bleeding side-effects, especially intracranial and gastrointestinal bleeding Secondary objective of the study is to evaluate whether a different prognostic profile, as determined by the MPI, is associated with 1) different kind of treatments for AF (no treatment vs anticoagulants, i.e. Vitamin K Antagonists (VKA) or novel oral anticoagulant (NOACs); and 2) differences in the main outcomes (i.e. mortality, major thromboembolic events and side effects including bleeding events).

Connect with a study center

  • S.C. Geriatria

    Genova, 16128
    Italy

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.